Events

Inotrem is excited to attend BIO-EUROPE, the largest gathering of biopharma professionals in Europe. Sven Zimmermann, CEO, and Marc Derive, Cofounder and CSO, are looking forward to meeting with you during this 3 days event: schedule a meeting via the official partnering portal.

ISICEM. March 21-24, 2023. Brussels. Inotrem will be attending the 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM) Symposium in Brussels. Since its first edition in 1980, ISICEM has become one of the largest meetings in its field, attracting more than 6200 participants from countries worldwide. This four-day

41st Annual J.P. Morgan HEALTHCARE CONFERENCE. January 9—12, 2023. San Francisco, CA. Inotrem is pleased to announce its participation in the 41st Annual J.P. Morgan Healthcare Conference in  San Francisco, CA. Sven Zimmermann, CEO, is scheduled to present on January 11, 2023 at 11:00 am Pacific Time results from the 2

Inotrem will attend Immunotherapies & Innovations For Infectious Diseases 6th Congress. It is looking forward to meeting you at its lecture presenting the results of its last two clinical trials, ASTONISH and ESSENTIAL, targeting TREM-1 for the treatment of Septic Shock and Critically-Ill COVID-19 patients.

Inotrem is pleased to attend the European Society of Intensive Care Medicine’s 35th Annual Congress in Paris where it will be holding a Symposium on “Targeting TREM-1 to Manage Life-Threatening Immune Disorders Caused by Severe Infections”

Inotrem welcomes you at the Symposium it will be holding during ISICIP 2022 on “Correcting Severe Immune Dysregulations in Sever Infections. The role of the TREM-1 Pathway. Applications in Septic Shock and COVID-10”.

March 1-2. 2022, Sachs European Life-Science CEO Forum (on line). Inotrem will participate to the 15th Annual European Life Sciences CEO Forum (ELSF) that will take place on the 1st-2nd of March 2022 and is part of the Sachs Spring Life Sciences Week. Inotrem is pleased to participate to this global bio-pharma industry event and, through

November 15-16. 2021. Lyon, France. Inotrem is pleased to participate to the fifth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2021). Fostering quality interactions between hundreds of pharmaceutical companies, research labs, service providers, technology developers, and clinicians, I4ID has become a central event contributing to the development of

March 16-17. 2021 (fully digital format). Inotrem is thrilled to participate to HYBRID 2021, the first Health Bioscience Research Industry Days that represents the complete ecosystem in life science in France, organized by ARIIS, AVIESAN, Leem, BPI France and France Biotech. During two days, researchers, biotech companies and representatives of

March 24. 2020. Brussels, Belgium. Inotrem will attend the 40th International Symposium on Intensive Care & Emergency Medicine which stands as one of the largest meeting in its field, attracting more than 6200 participants. During the Symposium, Inotrem will present a poster showing for the first time the association between

February 27-28, 2020. Washington DC. Inotrem will attend the 3CT Workshop (Critical Care Clinical Trialists) that will take place at the French Embassy on February 27th and 28th 2020 in Washington DC. During the 2-days Symposium, Inotrem will present the design of its ASTONISH Phase IIb clinical trial for Nangibotide

January 13-16, 2020. San Francisco. Inotrem will participate to the annual J.P. Morgan Healthcare Conference. It is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

December 3, 2019. Nancy. Cecile Jouclas, Inotrem’s Administrative and Financial Officer, will participate to the Deeptech Tour organized by the BPI. Cecile will be a host at the workshop “What tools to finance your deeptech project?” that will take place on the Université de Lorraine’s campus. Throughout France, the Deeptech

October 8-12 in Chania, Crete, Greece. Marc Derive, Co-founder and CSO of Inotrem, will present new preclinical data during the 18th ESS congress and 9th Congress of the IFSS, entitled “TREM-1 pharmacological inhibition by LR12/nangibotide improves survival and controls vascular leakage during experimental endotoxic shock in mice” in a session

28 September – 2 October 2019 in Berlin, Germany. European Society of Intensive Care Medicine’s (ESICM) annual congress attracts audiences of over 6,000 physicians, anesthetists, trainees and nursing and allied health professionals, every year, from every continent and 97 different countries. A diverse faculty of more than 300 international speakers

July 9. 2019 in Paris. Jean-Jacques Garaud, CEO at Inotrem, will be a speaker at the Solebury Trout Summer Investor tour, hosted by Andera Partners in Paris.